• Helpful online tools and downloadable, printable materials are available to you here. Visit our FAQs page to get answers to many of your frequently asked questions.

    • Mitigare<sup>®</sup> Sample Kit

      Mitigare® Sample Kit

      The free kit provides Mitigare® samples, patient materials and True Blue Savings details.

      REQUEST YOURS
    • Mitigare<sup>®</sup> True Blue Savings Materials

      Mitigare® True Blue Savings Materials

      Request copies of our Savings Card for your patients. They'll activate it online or by calling us.

      CONTACT US
    • Mitigare<sup>®</sup> Pharmacy Sell Sheet

      Mitigare® Pharmacy Sell Sheet

      Take a closer look at dispensing information for Mitigare® and its authorized generic.

      Download
    • CompleteCare Home Delivery Form

      CompleteCare Home Delivery Form

      Give this form to your patients who want to receive Mitigare® via home delivery.

      Download
    • CompleteCare Pharmacy Patient Card

      CompleteCare Pharmacy Patient Card

      Notifies your patient that you have sent their Mitigare® prescription to CompleteCare.

      REQUEST CARDS
    • Mitigare<sup>®</sup> Physician Brochure

      Mitigare® Physician Brochure

      Take a closer look at Mitigare® and the True Blue Savings program.

      Download
    • Mitigare<sup>®</sup> Medguide

      Mitigare® Medguide

      Download a copy of our Medication Guide for important information.

      Download
    • Mitigare<sup>®</sup> Prescribing Information

      Mitigare® Prescribing Information

      Download a copy of the Mitigare® Prescribing Information PDF.

      Download
    • Mitigare<sup>®</sup> Leave Behind

      Mitigare® Leave Behind

      Download a copy of the Mitigare® product detail and ISI PDF.

      Download

Go to All Resources

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.